TRCT
HRMY icon

Tower Research Capital (TRC)’s Harmony Biosciences HRMY Stock Holding History

Tower Research Capital (TRC)’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.6K Sell
1,801
-1,875
-51% -$59.1K ﹤0.01% 2536
2026
Q1 		$103K Buy
3,676
+3,026
+466% +$99.2K ﹤0.01% 2154
2025
Q4 		$24.3K Sell
650
-582
-47% -$19.1K ﹤0.01% 2958
2025
Q3 		$34K Sell
1,232
-2,279
-65% -$78.5K ﹤0.01% 2835
2025
Q2 		$111K Buy
3,511
+2,711
+339% +$87.2K ﹤0.01% 2294
2025
Q1 		$26.6K Sell
800
-3,059
-79% -$110K ﹤0.01% 2707
2024
Q4 		$133K Sell
3,859
-251
-6% -$8.62K ﹤0.01% 1987
2024
Q3 		$164K Sell
4,110
-8,351
-67% -$293K ﹤0.01% 1801
2024
Q2 		$376K Buy
12,461
+12,196
+4,602% +$367K 0.01% 1578
2024
Q1 		$8.9K Sell
265
-5,972
-96% -$192K ﹤0.01% 3936
2023
Q4 		$201K Buy
6,237
+3,666
+143% +$102K ﹤0.01% 2096
2023
Q3 		$84.3K Buy
2,571
+1,913
+291% +$66.4K ﹤0.01% 2108
2023
Q2 		$23.2K Sell
658
-4,709
-88% -$163K ﹤0.01% 3253
2023
Q1 		$175K Buy
5,367
+5,098
+1,895% +$232K 0.01% 1443
2022
Q4 		$14K Sell
269
-1,669
-86% -$91.8K ﹤0.01% 3508
2022
Q3 		$86K Buy
1,938
+549
+40% +$26.8K ﹤0.01% 2692
2022
Q2 		$68K Buy
1,389
+1,108
+394% +$49.9K ﹤0.01% 2605
2022
Q1 		$14K Sell
281
-203
-42% -$8.28K ﹤0.01% 3889
2021
Q4 		$21K Buy
484
+38
+9% +$1.51K ﹤0.01% 3602
2021
Q3 		$17K Sell
446
-1,266
-74% -$40.8K ﹤0.01% 3866
2021
Q2 		$48K Buy
1,712
+1,198
+233% +$35.9K ﹤0.01% 3053
2021
Q1 		$17K Buy
514
+308
+150% +$10.8K ﹤0.01% 4006
2020
Q4 		$7K Sell
206
-3,034
-94% -$122K ﹤0.01% 4488
2020
Q3 		$110K Buy
+3,240
New +$118K ﹤0.01% 3086

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC)'s HRMY Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Harmony Biosciences (HRMY) stake by 51% in Q2 2026, selling an estimated $59.1K and leaving 1,801 shares worth $65.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2536.

Tower Research Capital (TRC) first reported a position in HRMY in Q3 2020 and has held it in 24 quarters since. The position peaked at $376K in Q2 2024. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Tower Research Capital (TRC) held 1,801 shares of Harmony Biosciences worth $65.6K as of Q2 2026.
  • Tower Research Capital (TRC) sold 1,875 Harmony Biosciences shares in Q2 2026, an estimated $59.1K.
  • Harmony Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2536 holding.
  • Tower Research Capital (TRC) first reported a position in Harmony Biosciences in Q3 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Harmony Biosciences position peaked at $376K in Q2 2024.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.